scholarly journals Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer

ACS Nano ◽  
2018 ◽  
Vol 12 (4) ◽  
pp. 3714-3725 ◽  
Author(s):  
Joey Dacula Mangadlao ◽  
Xinning Wang ◽  
Christopher McCleese ◽  
Maria Escamilla ◽  
Gopalakrishnan Ramamurthy ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gold Nanoparticles ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane

scholarly journals Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles?

2019 ◽  
Vol 10 (35) ◽  
pp. 8119-8128 ◽  
Author(s):  
Dong Luo ◽  
Xinning Wang ◽  
Sophia Zeng ◽  
Gopalakrishnan Ramamurthy ◽  
Clemens Burda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Gold Nanoparticles ◽  
Prostate Specific Membrane Antigen ◽  
Cancer Radiotherapy ◽  
Size Dependent ◽  
High Affinity ◽  
Targeting Peptide ◽  
Prostate Cancer Radiotherapy ◽  
Size Matter ◽  
Specific Membrane

Prostate-Specific Membrane Antigen (PSMA) targeted radiosensitizers are developed for prostate cancer CT imaging and radiotherapy based on gold nanoparticles and a high-affinity targeting peptide, PSMA-1, revealing a size-dependent pattern.

479: Prostate-Specific Membrane Antigen (PSMA) Expression as a Predictor of Prostate Cancer Progression

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-156
Author(s):  
Matthias D. Hofer ◽  
Sven Perner ◽  
Haojie Li ◽  
Rainer Kuefer ◽  
Richard E. Hautmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cancer Progression ◽  
Specific Membrane ◽  
Psma Expression

scholarly journals 225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient

2021 ◽  
Vol 10 (5) ◽  
pp. 205846012110225
Author(s):  
Omer Aras ◽  
Stefan Harmsen ◽  
Richard Ting ◽  
Haluk B Sayman
Keyword(s):  
Prostate Cancer ◽  
Standard Of Care ◽  
Complete Response ◽  
Prostate Specific Membrane Antigen ◽  
Limited Data ◽  
Castrate Resistant Prostate Cancer ◽  
Targeting Peptide ◽  
Castrate Resistant ◽  
Specific Membrane

Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177Lu-PSMA-617. In addition, the patient’s baseline germline mutation likely predisposed him to more aggressive disease.

Sign in / Sign up

Export Citation Format

Share Document